HUP0002495A1 - Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use - Google Patents
Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their useInfo
- Publication number
- HUP0002495A1 HUP0002495A1 HU0002495A HUP0002495A HUP0002495A1 HU P0002495 A1 HUP0002495 A1 HU P0002495A1 HU 0002495 A HU0002495 A HU 0002495A HU P0002495 A HUP0002495 A HU P0002495A HU P0002495 A1 HUP0002495 A1 HU P0002495A1
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- vla
- cycloalkyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 108010016626 Dipeptides Proteins 0.000 title 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- -1 amino- Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
A találmány tárgya (I) és (IA) általános képletű vegyületekgyógyászati szempontból elfogadható sóik, és ezeket tartalmazógyógyászati készítmények. A képletekben R1 jelentése adott esetbenszubsztituált alkil-, aril-, cikloalkil-, heterociklusos- ésheteroarilcsoport; R2 jelentése hidrogénatom, adott esetbenszubsztituált alkil-, cikloalkil-, cikloalkenil-, heterociklusos-,aril- és heteroarilcsoport; vagy R1 és R2 jelentése a kapcsolódóatomokkal együtt adott esetben szubsztituált heterociklusoscsoport; R3jelentése hidrogénatom, adott esetben szubsztituált alkil-,cikloalkil-, aril-, heteroarilcsoport és heterociklusos csoport; vagyR2 és R3 jelentése a kapcsolódó atomokkal együtt adott esetbenszubsztituált telített heterociklusos csoport; R5 jelentése -ALK-Xvagy =CH2-Y általános képletű csoport; R6 jelentése 2,4-dioxo-tetrahidrofurán-3-yl(3,4-enol)-, amino-, alkoxi-, szubsztituáltalkoxi-, cikloalkoxi-, szubsztituált cikloalkoxi-, -O-(N-szukcinimidil)-, -NH-adamantil-, -O-koleszt-5-en-3-b-il- csoport, -NHOY általános képletű csoport; Q jelentése -C(X)NR7- általánosképletű csoport, ahol R7 jelentése hidrogénatom vagy alkilcsoport és Xjelentése oxigénatom vagy kénatom. A találmány szerinti vegyületekalkalmasak VLA-4 által közvetített gyulladásos megbetegedésekkezelésére. ÓThe subject of the invention is compounds of formulas (I) and (IA), their pharmaceutically acceptable salts, and pharmaceutical preparations containing them. In the formulas, R1 is an optionally substituted alkyl, aryl, cycloalkyl, heterocyclic and heteroaryl group; R 2 is a hydrogen atom, an optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl group; or R1 and R2 together with the attached atoms are optionally substituted heterocyclic groups; R3 is a hydrogen atom, optionally substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic groups; or R 2 and R 3 together with the attached atoms are optionally substituted saturated heterocyclic groups; R5 is a group of the general formula -ALK-X or =CH2-Y; R6 is 2,4-dioxo-tetrahydrofuran-3-yl(3,4-enol)-, amino-, alkoxy-, substituted-alkoxy-, cycloalkoxy-, substituted cycloalkoxy-, -O-(N-succinimidyl)-, -NH -adamantyl-, -O-cholest-5-en-3-b-yl- group, -NHOY group; Q is a group of the general formula -C(X)NR7-, where R7 is a hydrogen atom or an alkyl group and X is an oxygen atom or a sulfur atom. The compounds according to the invention are suitable for the treatment of inflammatory diseases mediated by VLA-4. HE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90441797A | 1997-07-31 | 1997-07-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0002495A1 true HUP0002495A1 (en) | 2000-12-28 |
| HUP0002495A3 HUP0002495A3 (en) | 2001-01-29 |
Family
ID=25419120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002495A HUP0002495A3 (en) | 1997-07-31 | 1998-07-31 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1001971A1 (en) |
| JP (1) | JP2001512135A (en) |
| KR (1) | KR20010022406A (en) |
| CN (1) | CN1265670A (en) |
| AU (1) | AU8585098A (en) |
| BR (1) | BR9812111A (en) |
| CA (1) | CA2290749A1 (en) |
| HU (1) | HUP0002495A3 (en) |
| IL (1) | IL133639A0 (en) |
| NO (1) | NO20000410L (en) |
| PL (1) | PL338373A1 (en) |
| WO (1) | WO1999006432A1 (en) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| US6093696A (en) * | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
| US6482849B1 (en) | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
| US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| DE69824037T2 (en) * | 1997-11-24 | 2005-06-02 | Merck & Co., Inc. | BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| WO1999043642A1 (en) | 1998-02-26 | 1999-09-02 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6545003B1 (en) | 1999-01-22 | 2003-04-08 | Elan Pharmaceuticals, Inc. | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| EP1144388B1 (en) | 1999-01-22 | 2010-01-13 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
| US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| JP2002535341A (en) * | 1999-01-26 | 2002-10-22 | エラン ファーマシューティカルズ，インコーポレイテッド | Pyroglutamic acid derivatives and related compounds that inhibit leukocyte adhesion mediated by VLA-4 |
| US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| DK1265606T3 (en) | 1999-08-13 | 2007-02-12 | Biogen Idec Inc | cell adhesion inhibitors |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| BR0016818A (en) | 1999-12-28 | 2002-10-01 | Pfizer Prod Inc | Non-peptidyl inhibitors of vla-4-dependent cell adhesion useful in the treatment of inflammatory, autoimmune and respiratory diseases |
| JP2003531141A (en) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | Enamine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| JP2004502762A (en) | 2000-07-07 | 2004-01-29 | セルテック アール アンド ディ リミテッド | Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
| JP2005022976A (en) * | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | Carboxylic acid derivative |
| MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
| ES2197003B1 (en) * | 2002-04-08 | 2005-03-16 | J. URIACH & CIA S.A. | NEW ANTAGONIST COMPOUNDS OF INTEGRINAS ALFA. |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| AU2008219007A1 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| BRPI0911652A2 (en) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Human serum albumin binders and their conjugates |
| EP3116910A1 (en) | 2014-03-13 | 2017-01-18 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| EP3436046A4 (en) * | 2016-04-01 | 2020-03-11 | The Regents of The University of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
| CN109516925B (en) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | Synthesis method of glutamic acid-1-methyl ester-5-tert-butyl ester |
| CN114605348B (en) * | 2022-05-12 | 2022-08-16 | 北京鑫开元医药科技有限公司 | Compounds having HDAC inhibitory activity, preparation method, compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2679903B1 (en) * | 1991-08-02 | 1993-12-03 | Elf Sanofi | DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
| WO1994007815A2 (en) * | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Small peptide anaphylatoxin receptor ligands |
| EP0673247A4 (en) * | 1992-12-01 | 1996-05-01 | Merck & Co Inc | Fibrinogen receptor antagonists. |
| JPH0873422A (en) * | 1994-09-07 | 1996-03-19 | Kdk Corp | New amino acid ester and method for detecting leukocyte, esterase or protease |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
-
1998
- 1998-07-31 HU HU0002495A patent/HUP0002495A3/en unknown
- 1998-07-31 EP EP98937053A patent/EP1001971A1/en not_active Withdrawn
- 1998-07-31 CN CN98807807A patent/CN1265670A/en active Pending
- 1998-07-31 KR KR1020007000986A patent/KR20010022406A/en not_active Application Discontinuation
- 1998-07-31 JP JP2000505187A patent/JP2001512135A/en not_active Withdrawn
- 1998-07-31 WO PCT/US1998/015325 patent/WO1999006432A1/en not_active Application Discontinuation
- 1998-07-31 PL PL98338373A patent/PL338373A1/en unknown
- 1998-07-31 IL IL13363998A patent/IL133639A0/en unknown
- 1998-07-31 AU AU85850/98A patent/AU8585098A/en not_active Abandoned
- 1998-07-31 CA CA002290749A patent/CA2290749A1/en not_active Abandoned
- 1998-07-31 BR BR9812111-1A patent/BR9812111A/en not_active IP Right Cessation
-
2000
- 2000-01-27 NO NO20000410A patent/NO20000410L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001512135A (en) | 2001-08-21 |
| NO20000410L (en) | 2000-03-28 |
| CN1265670A (en) | 2000-09-06 |
| PL338373A1 (en) | 2000-10-23 |
| IL133639A0 (en) | 2001-04-30 |
| HUP0002495A3 (en) | 2001-01-29 |
| NO20000410D0 (en) | 2000-01-27 |
| WO1999006432A1 (en) | 1999-02-11 |
| AU8585098A (en) | 1999-02-22 |
| EP1001971A1 (en) | 2000-05-24 |
| CA2290749A1 (en) | 1999-02-11 |
| KR20010022406A (en) | 2001-03-15 |
| BR9812111A (en) | 2000-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002495A1 (en) | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use | |
| HUP0003921A2 (en) | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use | |
| HUP0004259A2 (en) | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof | |
| HUP0002682A1 (en) | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| HUP0004529A2 (en) | Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use | |
| HUP9700602A1 (en) | New inhibitors of bone-resorption and vitronectine-receptor-antagonists | |
| HUP0301249A2 (en) | Benzamide compounds as apo b secretion inhibitors pharmaceutical compositions containing them and their use | |
| HUP0004531A2 (en) | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use | |
| HUP0104867A2 (en) | Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use | |
| HUP0002476A2 (en) | Amine compounds, their production and use | |
| DK0590919T3 (en) | Therapeutic agents for Parkinson's disease | |
| HUP0002272A2 (en) | Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use | |
| RS20060079A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
| HUP0102563A2 (en) | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation | |
| HUP0101999A2 (en) | 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them | |
| KR950010888A (en) | How to inhibit smooth muscle cell proliferation and restenosis | |
| HUP0100669A2 (en) | Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof | |
| DE68914292D1 (en) | Composition for the treatment of ischemic disorders in organs. | |
| HUP9802937A2 (en) | Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use | |
| EP0671390A3 (en) | Antithrombotic agents | |
| NO961000L (en) | Piperidine derivatives, process for their preparation and drug and preparation containing them | |
| ES2101073T3 (en) | NEW AZA-ANDROSTANO-DERIVATIVES 17-BETA-SUBSTITUTED. | |
| TR199801614T2 (en) | Peptide derivatives | |
| ES2073258T3 (en) | NEW DERIVATIVES OF THE UREA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. | |
| TW429255B (en) | Pyrazine compounds having treatment of central nervous system diseases and disorders |